Translational Neuroendocrinology
101 – 110 of 126
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2006
-
Mark
Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease.
(
- Contribution to journal › Letter
-
Mark
Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease
(
- Contribution to journal › Article
-
Mark
CART Regulates Islet Hormone Secretion and Is Expressed in the {beta}-Cells of Type 2 Diabetic Rats.
(
- Contribution to journal › Article
- 2005
-
Mark
Somatostatin, misoprostol and galanin inhibit gastrin- and PACAP-stimulated secretion of histamine and pancreastatin from ECL cells by blocking specific Ca(2+) channels.
(
- Contribution to journal › Article
-
Mark
Combining neuroprotective treatment of embryonic nigral donor tissue with mild hypothermia of the graft recipient.
(
- Contribution to journal › Article
-
Mark
Proteolysis of NR2B by calpain in the hippocampus of epileptic rats.
(
- Contribution to journal › Article
-
Mark
Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease.
(
- Contribution to journal › Article
-
Mark
The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient {beta}-cell mass and exocytosis.
(
- Contribution to journal › Article
-
Mark
Orexin loss in Huntington's disease.
(
- Contribution to journal › Article
-
Mark
Euploidy in somatic cells from R6/2 transgenic Huntington's disease mice
(
- Contribution to journal › Article